Literature DB >> 1596938

Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.

M Papanastasiou1, C N Baxevanis, M Papamichail.   

Abstract

The effect of prothymosin alpha (ProT alpha) on the survival of DBA/2 mice inoculated with syngeneic tumour cells was studied. DBA/2 mice inoculated intraperitoneally (i.p.) with 2 x 10(5) syngeneic leukaemic L1210 cells developed ascites within 8-12 days and died 10-14 days later. Treatment with ProT alpha consistently inhibited the development of ascites in 20% of the treated animals and prolonged the survival of 40%-60% of the animals up to 70 days. The most effective treatment schedule of ProT alpha was 300 ng/mouse given i.p. at 2-day intervals for 3 weeks followed by a rest period of 7 days, prior to tumour cell inoculation. Peritoneal exudate (PE) cells collected from mice treated with the optimal dose of ProT alpha produced, in the absence of exogenous stimulus, six- to eightfold higher levels of tumour necrosis factor alpha (TNF alpha) than PE cells from control mice. Furthermore these cells exhibited cytotoxic activity against several tumour cell lines including the syngeneic L1210, the TNF-insensitive P815 mastocytoma, the human MOLT-4 lymphoblastic leukaemia, as well as the murine TNF-sensitive L929 fibroblast cell line. Kinetic studies revealed that both production of TNF alpha and tumoricidal activity peaked 7 days after the last injection of ProT alpha and were maintained at high levels over a period of 1 month. Injections with 150 ng ProT alpha slightly improved the survival of mice whereas higher (500 ng and 1000 ng) doses of ProT alpha and a wide range of thymosin alpha 1 doses remained without any effect. PE cells collected from these mice produced extremely low levels of TNF alpha and exhibited negligible tumoricidal activity. Our data demonstrate that ProT alpha has a protective effect in vivo against the growth of adoptively transferred tumour cells and suggest that this effect is, at least in part, mediated by ProT alpha-activated PE cells. These cells were demonstrated to produce high levels of TNF alpha in vitro and to exhibit activity against both TNF-sensitive and TNF-resistant cell lines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596938     DOI: 10.1007/bf01741862

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor.

Authors:  S Hosoe; T Ogura; S Hayashi; K Komuta; T Ikeda; T Shirasaka; I Kawase; T Masuno; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Enhancement of human T lymphocyte functions by prothymosin alpha. I. Augmentation of mixed lymphocyte culture reactions and soluble protein-induced proliferative responses.

Authors:  C N Baxevanis; G J Reclos; C Panneerselvam; M Papamichail
Journal:  Immunopharmacology       Date:  1988 Mar-Apr

3.  Human prothymosin alpha: amino acid sequence and immunologic properties.

Authors:  L X Pan; A A Haritos; J Wideman; T Komiyama; M Chang; S Stein; S B Salvin; B L Horecker
Journal:  Arch Biochem Biophys       Date:  1986-10       Impact factor: 4.013

4.  Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.

Authors:  A A Haritos; G J Goodall; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

5.  Distribution of prothymosin alpha in rat tissues.

Authors:  A A Haritos; O Tsolas; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

6.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

7.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.

Authors:  B D Williamson; E A Carswell; B Y Rubin; J S Prendergast; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

8.  The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA.

Authors:  W H Eschenfeldt; S L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages.

Authors:  T Decker; M L Lohmann-Matthes; G E Gifford
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

10.  Mechanism of action of prothymosin alpha in the human autologous mixed lymphocyte response.

Authors:  C N Baxevanis; G J Reclos; M Economou; P Arsenis; A Katsiyiannis; K Seferiades; G Papadopoulos; O Tsolas; M Papamichail
Journal:  Immunopharmacol Immunotoxicol       Date:  1988       Impact factor: 2.730

View more
  7 in total

1.  Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.

Authors:  K Eckert; E Grünberg; P Immenschuh; F Garbin; E D Kreuser; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid.

Authors:  Yanwen Jin; Cheng Cao; Ping Li; Xuan Liu; Wei Huang; Chufang Li; Qingjun Ma
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

Review 3.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

4.  Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G Spanakos; O E Tsitsilonis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

5.  Induction of lymphokine-activated killer activity in mice by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G V Dedoussis; N G Papadopoulos; O Tsolas; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 6.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

7.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.